Severe Asthma Spotlight-New Updates in Asthma Guidelines (EPR-4)

Video Transcription

Video Summary

In this talk, the speaker discusses the use of single maintenance and relief therapy (SMART) in the management of asthma. SMART therapy involves using an inhaled corticosteroid (ICS) as a maintenance medication and as-needed for reliever medication. The speaker emphasizes the importance of adhering to the expert panel guidelines and highlights that SMART therapy is recommended for patients with persistent asthma who are using a short-acting beta-agonist (SABAM) more than twice a week. The speaker also notes that SMART therapy can improve asthma outcomes, including reducing exacerbations and improving lung function. They mention that Formoterol, a long-acting beta-agonist (LABA) with a rapid onset of action, is the preferred LABA for use in SMART therapy. However, they acknowledge that there may be challenges in implementing SMART therapy, such as cost, formulary availability, and insurance coverage. Finally, the speaker discusses future directions in asthma therapy, including the potential use of LAMA (long-acting muscarinic antagonist) in SMART therapy and the exploration of ultra-LABAs with shorter onset of action.

Meta Tag

Category Allergy and Airway

Speaker Daniel Ouellette, MD, MS, FCCP

Speaker Shahid Sheikh, MD, FCCP

Speaker Mariam Louis, MD, FCCP

Speaker Nauman Chaudary, MBBS, FCCP

Keywords

SMART

asthma management

inhaled corticosteroid

maintenance medication

reliever medication

persistent asthma

Formoterol

LABA

exacerbations